U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H16Cl2F2N4O2
Molecular Weight 429.248
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of UPROSERTIB

SMILES

CN1N=CC(Cl)=C1C2=C(Cl)OC(=C2)C(=O)N[C@H](CN)CC3=CC=C(F)C(F)=C3

InChI

InChIKey=AXTAPYRUEKNRBA-JTQLQIEISA-N
InChI=1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)/t10-/m0/s1

HIDE SMILES / InChI
Molecular Formula C18H16Cl2F2N4O2
Molecular Weight 429.248
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Uprosertib is an oral potent Akt inhibitor which acts equally on Akt1, Akt2 and Akt3. The drug is under clinical development in combination with trametinib for the treatment of different cancers, including melanoma, myeloma, breast, endometrial, cervical cancer, etc.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 180.0 nM [IC50]
Inhibitor
8504
 38.0 nM [IC50]
Inhibitor
8504
 328.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
409 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29611022
75 mg 1 times / day steady-state, oral
dose: 75 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
UPROSERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
94.6 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29611022
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
UPROSERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6383 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29611022
75 mg 1 times / day steady-state, oral
dose: 75 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
UPROSERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1262 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29611022
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
UPROSERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
63.7 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29611022
75 mg 1 times / day steady-state, oral
dose: 75 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
UPROSERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY34176
https://www.001chemical.com/chem/search?q=DY34176
1PlusChem LLC
1P008TXF
https://www.1pchem.com/search?query=1P008TXF
AbovChem LLC
HY-15965A
http://www.abovchem.com/pc/en/product_list.aspx?wd=HY-15965A
ApexBio Technology
B3590
https://www.apexbt.com/catalogsearch/result/?q=B3590
AstaTech
C14076
http://astatechinc.com/CPSResult.php?CRNO=C14076
AstaTech
F20800
http://astatechinc.com/CPSResult.php?CRNO=F20800
BLD Pharm
BD629859
http://www.bldpharm.com/search/Search.html?keyword=BD629859
Cayman Chemical
19904
http://www.caymanchem.com/app/template/Product.vm/catalog/19904
Chem Scene
CS-3087
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-3087
ChemShuttle
140504
https://www.chemshuttle.com/catalogsearch/result/?q=140504
eMolecules
259932074
https://orderbb.emolecules.com/search/#?query=259932074
eMolecules
261291586
https://orderbb.emolecules.com/search/#?query=261291586
eMolecules
301184989
https://orderbb.emolecules.com/search/#?query=301184989
eMolecules
50282260
https://orderbb.emolecules.com/search/#?query=50282260
eMolecules
50283411
https://orderbb.emolecules.com/search/#?query=50283411
Excenen
EX-A1593
http://www.excenen.com/searchresultlist.php?id=EX-A1593
Excenen
EX-A1594
http://www.excenen.com/searchresultlist.php?id=EX-A1594
KeyOrganics
AS-56172
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-56172
mcule
MCULE-4911475447
https://mcule.com/MCULE-4911475447/
mcule
MCULE-6902422433
https://mcule.com/MCULE-6902422433/
mcule
MCULE-7696692757
https://mcule.com/MCULE-7696692757/
mcule
MCULE-8077537701
https://mcule.com/MCULE-8077537701/
MedChem Express
HY-15965
https://www.medchemexpress.com/search.html?q=HY-15965&ft=&fa=&fp=
Molcore
MC34176
http://www.molcore.com/CatMC34176.html
Molnova
M17123
https://www.molnova.com/en/serch-list.html?keywords=M17123
MolPort
MolPort-044-560-307
https://www.molport.com/shop/molecule-link/MolPort-044-560-307
MolPort
MolPort-044-568-073
https://www.molport.com/shop/molecule-link/MolPort-044-568-073
MuseChem
I009962
https://www.musechem.com/product/I009962.html
Selleck Chemicals
S7492
http://www.selleckchem.com/search.html?searchDTO.searchParam=S7492
ShangHai Biochempartner
BCP28203
http://www.biochempartner.com/search_BCP28203
ShangHai Biochempartner
BCP28204
http://www.biochempartner.com/search_BCP28204
TargetMol
T6849
https://www.targetmol.com/search?keyword=T6849
PubMed

PubMed

TitleDatePubMed
Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.
2014
Patents

Patents

08273782
5
08410158
5
20090209607
4

Sample Use Guides

In Vivo Use Guide
Melanoma: patients receive oral uprosertib at a dose 25 mg daily. Cervical Cancer: the dose is 50 mg orally once per day.
Route of Administration: Oral
In Vitro Use Guide
Human lung fibroblasts were treated with uprosertib in concentration range from 20 nM to 1.28 uM and analyzed for type I collagen expression. At concentration of 320 nM or higher the drug reduced intracellular level of collagen alpha2(I) polypeptide, while it reduced intracellular alpha olypeptide at concentrations > 640 nM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:46:57 GMT 2025
Edited
by admin
on Mon Mar 31 21:46:57 GMT 2025
Record UNII
ZXM835LQ5E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
uprosertib [INN]
Preferred Name English
UPROSERTIB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
AKT INHIBITOR GSK-2141795
Common Name English
2-FURANCARBOXAMIDE, N-((1S)-2-AMINO-1-((3,4-DIFLUOROPHENYL)METHYL)ETHYL)-5-CHLORO-4-(4-CHLORO-1-METHYL-1H-PYRAZOL-5-YL)-
Systematic Name English
GSK-2141795C
Code English
UPROSERTIB [USAN]
Common Name English
Uprosertib [WHO-DD]
Common Name English
GSK2141795
Code English
AKT INHIBITOR GSK2141795
Common Name English
GSK2141795C
Code English
N-[(1S)-1-(Aminomethyl)-2-(3,4-difluorophenyl)ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)furan-2-carboxamide
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C155764
Created by admin on Mon Mar 31 21:46:57 GMT 2025 , Edited by admin on Mon Mar 31 21:46:57 GMT 2025
Code System Code Type Description
USAN
AB-111
Created by admin on Mon Mar 31 21:46:57 GMT 2025 , Edited by admin on Mon Mar 31 21:46:57 GMT 2025
PRIMARY
INN
9942
Created by admin on Mon Mar 31 21:46:57 GMT 2025 , Edited by admin on Mon Mar 31 21:46:57 GMT 2025
PRIMARY
DRUG BANK
DB11969
Created by admin on Mon Mar 31 21:46:57 GMT 2025 , Edited by admin on Mon Mar 31 21:46:57 GMT 2025
PRIMARY
PUBCHEM
51042438
Created by admin on Mon Mar 31 21:46:57 GMT 2025 , Edited by admin on Mon Mar 31 21:46:57 GMT 2025
PRIMARY
ChEMBL
CHEMBL3137336
Created by admin on Mon Mar 31 21:46:57 GMT 2025 , Edited by admin on Mon Mar 31 21:46:57 GMT 2025
PRIMARY
FDA UNII
ZXM835LQ5E
Created by admin on Mon Mar 31 21:46:57 GMT 2025 , Edited by admin on Mon Mar 31 21:46:57 GMT 2025
PRIMARY
CAS
1047634-65-0
Created by admin on Mon Mar 31 21:46:57 GMT 2025 , Edited by admin on Mon Mar 31 21:46:57 GMT 2025
PRIMARY
SMS_ID
100000174861
Created by admin on Mon Mar 31 21:46:57 GMT 2025 , Edited by admin on Mon Mar 31 21:46:57 GMT 2025
PRIMARY
NCI_THESAURUS
C84870
Created by admin on Mon Mar 31 21:46:57 GMT 2025 , Edited by admin on Mon Mar 31 21:46:57 GMT 2025
PRIMARY
Related Record Type Details
RAC-BETA SERINE/THREONINE-PROTEIN KINASE
TARGET -> INHIBITOR
Structure of UPROSERTIB HYDROCHLORIDE
SALT/SOLVATE -> PARENT
RAC-ALPHA SERINE/THREONINE-PROTEIN KINASE
TARGET -> INHIBITOR
RAC-GAMMA SERINE/THREONINE-PROTEIN KINASE
TARGET -> INHIBITOR
Related Record Type Details
Structure of UPROSERTIB
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966